This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Alogliptin with metformin oral

Updated 2 Feb 2023 | Biguanides DPP-4 inhibitors


Tablets containing alogliptin and metformin.

Drugs List

  • alogliptin 12.5mg and metformin 1000mg tablets
  • VIPDOMET 12.5mg+1000mg tablets
  • Therapeutic Indications


    Type 2 diabetes (NIDDM) not controlled by diet,weight loss & exercise alone

    Dual therapy:
    For the treatment of type 2 diabetes as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already treated with combination of alogliptin and metformin.

    Triple therapy:
    For the treatment of type 2 diabetes in combination with pioglitazone as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone.

    With Insulin:
    For the treatment of type 2 diabetes in combination with insulin when diet, exercise and stable dosage of insulin and metformin alone do not provide adequate glycaemic control.



    One tablet of twice daily, corresponding to a daily dose of 25mg alogliptin plus 2g metformin.

    The maximum recommended daily dose of 25mg alogliptin should not be exceeded.

    Patients with Renal Impairment

    GFR 60 to 89ml/minute Metformin: Maximum daily dose is 3000mg. Dose reduction may be considered in relation to declining renal function. Alogliptin: No dose adjustment. Maximum daily dose is 25mg. GFR 45 to 59ml/minute Metformin: Maximum daily dose is 2000mg. The starting dose is at most half of the maximum dose. Alogliptin: Maximum daily dose is 12.5mg. GFR 30 to 44ml/minute Metformin: Maximum daily dose is 1000mg. The starting dose is at most half of the maximum dose. Alogliptin: Maximum daily dose is 12.5mg.

    GFR below 30ml/minute
    Combination is contraindicated.
    Metformin: Contraindicated.
    Alogliptin: Maximum daily dose 6.25mg.

    Additional Dosage Information

    When alogliptin is used in combination with metformin and/or a thiazolidinedione, the dose of metformin and/or the thiazolidinedione should be maintained. However, in case of hypoglycaemia while the patient is treated with triple therapy, a lower dose of metformin or thiazolidinedione may be considered.

    When co-administered with insulin, a lower dose of insulin may be considered to reduce the risk of hypoglycaemia.


    Acute alcohol intoxication
    Children under 18 years
    Severe infection
    Within 48 hours of using iodinated contrast media
    Cardiac failure
    Diabetic ketoacidosis
    Diabetic pre-coma
    Hepatic impairment
    Lactic acidosis
    Recent myocardial infarction
    Renal impairment - glomerular filtration rate below 30ml/minute
    Respiratory failure

    Precautions and Warnings

    History of pancreatitis
    Renal impairment - glomerular filtration rate 30 to 59 ml/minute

    Reduce dose in patients with moderate renal impairment
    Advise ability to drive/operate machinery may be affected by side effects
    Test vit B12 levels if deficiency is suspected or risk factors are present
    Monitor renal function before treatment and regularly during treatment
    If hepatic impairment symptoms occur monitor LFT & consider discontinuation
    Monitor for development of lactic acidosis
    Monitor hepatic function
    Monitor renal function 3 to 6 monthly in elderly patients
    Monitor renal function 3- 6 monthly if renal function is borderline normal
    Monitor renal function annually in patients with normal renal function
    Advise patient to report symptoms of low vitamin B12 levels
    Advise patient/carer to report immediately symptoms of lactic acidosis
    Advise patients to report symptoms of acute pancreatitis immediately
    Discontinue if pemphigus-type reactions develop
    Discontinue permanently if acute pancreatitis occurs
    Withhold until at least 48hrs after general, spinal or epidural anaesthesia
    Discontinue if lactic acidosis is suspected
    Discontinue if pancreatitis is suspected
    If dehydration occurs, discontinue treatment until patient has recovered
    Advise patient to avoid alcohol during treatment
    Patient to inform DVLA if fitness to drive impaired or hypoglycaemic risk

    Lactic acidosis can occur due to metformin accumulation. To reduce the incidence of this occurring, patients should be assessed for risk factors associated with the development of lactic acidosis and monitored regularly. Symptoms of lactic acidosis include acidotic dyspnoea, abdominal pain, hypothermia and coma. Risk factors for lactic acidosis include poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic impairment and any condition associated with hypoxia.

    A diagnosis of lactic acidosis should be considered in the presence of non-specific symptoms such as muscle cramps, digestive disorders, abdominal pain or severe asthenia. Lactic acidosis is also indicated by decreased blood pH, plasma lactate levels above 5mmol/L and an increased anion gap and lactate pyruvate ratio.

    Special caution should be exercised in situations where renal function may become impaired, e.g. when starting therapy with a non-steroidal anti-inflammatory drug (NSAID).

    Patients with heart failure are at an increased risk of hypoxia and renal insufficiency. Treatment is contraindicated in patients with acute or unstable heart failure but may be used in patients with stable chronic heart failure provided cardiac and renal function is regularly monitored.

    Pregnancy and Lactation


    Alogliptin with metformin is contraindicated in pregnancy.
    Manufacturer advises to avoid the use of alogliptin with metformin during pregnancy.
    At the time of writing there are no data from the use of alogliptin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.
    Metformin is generally considered to present a low risk when used during pregnancy (Briggs, 2015) and animal data generally do not indicate harmful effects on pregnancy, embryonal or foetal development, parturition or postnatal development. Rare cases of neural tube defects and malformations of the heart and eye have been seen in animals though studies in pregnant women indicate a low risk to the foetus. The manufacturer states that metformin is not recommended for the treatment of diabetes in pregnancy as it does not provide adequate maternal glycaemic control and insulin therapy is preferred.
    Detailed guidance on the treatment of diabetes during pregnancy is available from the National Institute for Health and Clinical Excellence (NICE) at


    Alogliptin with metformin is contraindicated in breastfeeding.
    Manufacturer advises that a decision must be made to either stop breastfeeding or discontinue alogliptin with metformin.
    It is unknown whether alogliptin is excreted in human breast milk. Animal studies have shown excretion of alogliptin and/or metabolite in milk, a risk to the nursing infant cannot be excluded.
    Metformin is known to be excreted in breast milk, and has occasionally been detected in low-levels in the serum of breastfed infants, although studies have found no adverse effects in infants breastfed by women taking metformin. LactMed recommends that caution be used in mothers with newborn and premature infants, and infants with renal impairment when metformin is taken.


    Advise patient to report symptoms of acute pancreatitis (severe, persistent abdominal pain).

    Advise patient to avoid alcohol during treatment.

    Advise patient that the ability to drive or operate machinery may be impaired.

    Advise patient to report symptoms of lactic acidosis such as acidotic dyspnoea, abdominal pain, muscle cramps, asthenia and hypothermia.

    Advise patient to report symptoms of low vitamin B12 levels.

    Advise patients to temporarily discontinue treatment in case of dehydration (severe diarrhoea or vomiting, fever or reduced fluid intake) and to contact a healthcare professional for advice.

    Advise patient to report to DVLA if there is a risk of hypoglycaemia, or if fitness to drive may be impaired due to diabetes complications. Guidance can be found by accessing website.

    Side Effects

    Abdominal pain
    Abnormal liver function tests
    Acute pancreatitis
    Anaphylactic reaction
    Bullous pemphigoid
    Decreased appetite
    Decreased vitamin-B12 absorption
    Erythema multiforme
    Exfoliative dermatitis
    Gastroesophageal reflux disease
    Hepatic failure
    Hepatic impairment
    Hypersensitivity reactions
    Lactic acidosis
    Metallic taste
    Stevens-Johnson syndrome
    Upper respiratory tract infection


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: March 2019

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3rd edition (2015) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Summary of Product Characteristics: Vipdomet 12.5mg/1000mg film coated tablets. Takeda UK Ltd. Revised March 2021.

    EMA Safety Update December 2016
    Available at:
    Last accessed: 18 January 2017

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Metformin. Last revised: 31 October 2018
    Last accessed: 18 March 2019

    MHRA Drug Safety Update June 2022
    Available at:
    Last accessed: 21 July 2022

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.